A Network Meta-Analysis of Different Psychological Therapies for Death Anxiety in Older Adults.

Omega (Westport)Feb 3, 2025 (epub)
Clinical ResearchGeriatricsPsychiatry

Jinhong Lu, Youzhuan Yang, Hongchao Ma

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis compared psychosocial therapies for death anxiety in older adults, drawing on seven randomized controlled trials involving 266 participants. Searches covered the earliest available records through July 2024. The analysis found that teaching components of spiritual intelligence therapy ranked highest for reducing death anxiety, with a SUCRA value of 99.6%. The authors concluded that this approach had the most favorable efficacy ranking among the therapies assessed.

Key findings

  • Seven randomized controlled trials with 266 older adults were included in the network meta-analysis.
  • Teaching components of spiritual intelligence therapy ranked highest for reducing death anxiety (SUCRA: 99.6%).

Why it matters

Death anxiety is a psychological outcome relevant to older adults, and this analysis compares several psychosocial approaches rather than evaluating one therapy in isolation. Its ranking may help inform discussion of therapeutic options, while the limited evidence base means the result should be interpreted as comparative evidence from a small set of trials, not definitive proof of superiority.

What to keep in mind

The analysis included only seven trials and 266 participants, limiting the evidence base for comparing therapies.

Source

Published in Omega (Westport). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.